🌫️ Adenocarcinoma of the lung is rising among smokers and non‑smokers alike.
Smoking remains the leading cause, but radon, genetics, and environmental hazards also play a major role. Our new post explores the causes, risk factors, and prevention strategies for the most common type of lung cancer.
Explore more 👇https://blog.banishcancer.org/causes-risk-factors-adenocarcinoma-lung/
#LungCancer #Adenocarcinoma #Oncology #CancerPrevention #PublicHealth #BanishCancer
Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer usually only detected at an advanced and metastatic state. This study shows that the chromatin regulator SAMD1 represses genes related to the epithelial-mesenchymal transition (EMT), thereby inhibiting cellular migration, and is downregulated during PDAC progression by the E3 ligase FBXO11.
Cholesterol is important for cancer progression, yet its levels are low in the lung. How is this overcome during lung cancer? This study shows that exogenous cholesterol can be sensed by lung adenocarcinoma cells, leading to activation of de novo cholesterol biosynthesis through a GLI2-FOXA3-HMGCS1 transcriptional axis, thereby promoting cancer progression.
Several studies suggest that bariatric surgery may lower risk of obesity-related cancers, but it's role in #prevention of #esophageal #cancer is less clear. A multinational Scandanavian study observed that gastric bypass surgery was associated with a decreased risk of esophageal #adenocarcinoma over time after surgery, compared to both the background population and non-operated individuals with morbid obesity.
This large multinational observational study investigated whether bariatric surgery was associated with reduced risk of esophageal and cardia adenocarcinoma (ECA) in individuals diagnosed with “morbid” obesity. The study involved a cohort of almost 750,000 persons from Sweden, Finland, and Denmark, grouped based on whether they underwent bariatric surgery (n=
Very exciting that this paper is out now in #cancercell: https://www.cell.com/cancer-cell/fulltext/S1535-6108(23)00216-7
In brief: we show that in esophageal #adenocarcinoma #checkpoint #therapy success is predicted by an independent combination of mutation burden and the amount of #monocytes in the tumour pre-treatment (as measured by RNAseq). Very exciting link between #myeloid cells and #immune response to #cancer!
Can we rely on contrast-enhanced CT to identify #pancreatic ductal #adenocarcinoma? (Max LeBlanc et al.)
Want to read more? Click the link below 👇
https://link.springer.com/article/10.1007/s00330-023-09758-y
Objectives To determine the sensitivity of contrast-enhanced computed tomography (CECT) in detecting pancreatic ductal adenocarcinoma (PDAC) and identify factors associated with false negatives (FNs). Methods Patients diagnosed with PDAC in 2014–2015 were retrospectively identified by a cancer registry. CECTs performed during the diagnostic interval were retrospectively classified as true positive (TP), indeterminate, or FN. Sensitivity TP/(TP+FN) was calculated for all CECTs and the following subgroups: protocol (uniphasic vs. biphasic); tumor size (≤ 2 cm vs. > 2 cm); and resectability (potentially resectable vs. unresectable). Multivariate logistic regression was performed to assess which of the following factors were associated with FN: clinical suspicion of PDAC; size >2 cm; presence of metastases; protocol; isoattenuating tumor; and potentially resectable disease on imaging. Results In total, 176 CECTs (127 uniphasic; 49 biphasic) in 154 patients (90 men, mean age 72 ± 11 years) were included. Sensitivity was 125/149 (83.9%) overall and 87/106 (82.1%) and 38/43 (88.4%) for uniphasic and biphasic protocols, respectively. Sensitivity was decreased for tumors ≤ 2 cm (45.4% vs. 90.6%), no liver metastases (78.0% vs. 95.9%), and potentially resectable disease (65.3% vs. 93.0%). Factors significantly associated with FN were clinical suspicion (OR, 0.24, 95% CI: 0.07–0.75), size>2 cm (OR, 0.10, 95% CI: 0.02–0.44), absence of liver metastases (OR, 4.94, 95% CI: 1.29–22.99), and potentially resectable disease (OR, 4.13, 95% CI: 1.07–16.65). Conclusions In our population, the overall sensitivity of CECT to detect PDAC is 83.9%; however, this is substantially lower in several scenarios, including patients with potentially resectable disease. This finding has important implications for patient outcomes and efforts to maximize CECT sensitivity should be sought. Clinical relevance statement The sensitivity of CECT to detect PDAC is significantly decreased in the setting of sub-2 cm tumors and potentially resectable disease. A dedicated biphasic pancreatic CECT protocol has higher sensitivity and should be applied in patients with suspected pancreatic disease. Key Points • The sensitivities of contrast-enhanced CT for the detection of PDAC were 87/106 (82.1%) and 38/43 (88.4%) for uniphasic and biphasic protocols, respectively. • The sensitivity of contrast-enhanced CT was decreased for small tumors ≤ 2 cm (45.4% vs. 90.6%), if there were no liver metastases (78.0% vs. 95.9%), and with potentially resectable disease (65.3% vs. 93.0%). • Absence of liver metastases (OR, 4.94, 95% CI: 1.29–22.99) and potentially resectable disease (OR, 4.13, 95% CI: 1.07–16.65) were associated with a false--negative (FN) CT result; suspicion of malignancy on the imaging requisition (OR, 0.24, 95% CI: 0.07–0.75) and size > 2 cm (OR, 0.10, 95% CI: 0.02–0.44) were negatively associated with FN.
Breath-hold PET acquisition shown as a practical way to minimize motion artifacts in PET, which has the potential to improve lesion detection for stage IA #pulmonary #adenocarcinoma. (Zhaoping Cheng et al.)
#InsightsIntoImaging #LungCancer
đź”— https://insightsimaging.springeropen.com/articles/10.1186/s13244-023-01446-1
Background Respiratory motion during PET acquisition may result in image blurring and resolution loss, reduced measurement of radiotracer uptake, and consequently, inaccurate lesion quantification and description. With the introduction of the total-body PET system, short-time PET acquisition is feasible due to its high sensitivity and spatial resolution. The purpose of this study was to evaluate the additional value of 20-s breath-hold (BH) lung PET in patients with stage IA pulmonary adenocarcinoma. Methods Forty-seven patients with confirmed stage IA pulmonary adenocarcinoma were enrolled in this retrospective study. All patients underwent a 300-s FB whole-body PET, followed by a BH lung PET. The SUVmax, TBR of the lesions and the percentage difference in nodule SUVmax (%ΔSUVmax) and TBR (%ΔTBR) between the two acquisitions was also calculated. The lesions were further divided by distance from pleura for subgroup analysis. The lesion detectability on PET images was the percentage of FDG-positive lesions. Results Among 47 patients, the BH lung PET images identified all lung nodules, and there was a significant difference in overall nodule SUVmax and TBR between BH PET and FB PET (both p < 0.01). The %ΔSUVmax and %ΔTBR were significantly higher in nodules adjacent to pleura (≤ 10 mm in distance) than those away from pleura (both p < 0.05). The lesion detectability of BH lung PET was significantly higher than that of FB PET (p < 0.01). Conclusion BH PET acquisition is a practical way to minimize motion artifacts in PET which has the potential to improve lesion detection for stage IA pulmonary adenocarcinoma. Critical relevance statement BH PET acquisition is a practical way to minimize motion artifacts in PET which has the potential to improve lesion detection for stage IA pulmonary adenocarcinoma. Graphical Abstract
Banish Cancer
ZPONZ
PLOS Biology
El Club De Los FĂsicos Muertos
Thomas Vaughan
Benjamin S-B 
European Radiology
Insights Into Imaging